Studies what raises the risk of progressive lung scarring in interstitial lung disease
Follows adults with interstitial lung disease to learn risks of progressive lung scarring.
Plain-language title generated from the registry record
Registry title: A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
Key facts
- Where
- Jinan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05895409, who can take part
Where in China
- The First Affiliated Hospital of Shandong First Medical UniversityJinan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qianfoshan Hospital
- Trial code
- NCT05895409
- Record updated
- 18 November 2023
- Original description
The goal of this observational study is to learn about risk of progressive pulmonary fibrosis (PPF). The main questions it aims to answer are:Read full original descriptionShow less
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
The goal of this observational study is to learn about risk of progressive pulmonary fibrosis (PPF). The main questions it aims to answer are:
* Risk factors of PPF * Prevalence of PPF * Mortality of PPF
Patients with interstitial lung disease (ILD) of known or unknown etiology other than IPF who has radiological evidence of pulmonary fibrosis will enroll in this study.
* All participants will have baseline investigations at the first visit having provided informed consent. * At the first visit, baseline characteristics will be collected including demographics, medical history, smoking history, complications and medication use. 50 mL of blood will be obtained. High resolution computed tomography (HRCT), full lung function tests and a 6 min walk test will be performed. * Further visits at 6 months and 12 months will include further 50 mL blood sampling. HRCT, full lung function tests and a 6 min walk test will be repeated.
Inclusion: 18-80 years old; Agree and sign the informed consent form; Interstitial lung disease patients with imaging features of pulmonary fibrosis.
Exclusion: mental illness or cognitive impairment; Patients with idiopathic pulmonary fibrosis (IPF); Pregnant or lactating women; participating in other clinical studies; Unable to sign informed consent form.